These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 35581455)

  • 41. Development and delivery of a pharmacist training program to increase naloxone access in Kentucky.
    Palmer E; Hart S; Freeman PR
    J Am Pharm Assoc (2003); 2017; 57(2S):S118-S122. PubMed ID: 28161300
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evaluation of naloxone furnishing community pharmacies in San Francisco.
    Nguyen AM; Kearney TE; Apollonio DE
    J Am Pharm Assoc (2003); 2020; 60(6):1050-1057.e1. PubMed ID: 32948461
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Naloxone for Opioid Overdose: Comment.
    Milas BL; Varon AJ
    Anesthesiology; 2024 Apr; 140(4):857. PubMed ID: 38335038
    [No Abstract]   [Full Text] [Related]  

  • 44. Naloxone for Opioid Overdose: Comment.
    Pattullo GG
    Anesthesiology; 2024 Apr; 140(4):856. PubMed ID: 38335034
    [No Abstract]   [Full Text] [Related]  

  • 45. Naloxone availability in independent community pharmacies in Georgia, 2019.
    Gilbert L; Elliott J; Beasley L; Oranu E; Roth K; Nguyễn J
    Subst Abuse Treat Prev Policy; 2021 Aug; 16(1):63. PubMed ID: 34419089
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Patient acceptance of naloxone resulting from targeted intervention from community pharmacists to prevent opioid misuse and accidental overdose.
    Skoy E; Werremeyer A; Steig J; Eukel H; Frenzel O; Strand M
    Subst Abus; 2021; 42(4):672-677. PubMed ID: 33044896
    [No Abstract]   [Full Text] [Related]  

  • 47. Impact of a statewide community pharmacy approach to opioid harm reduction.
    Sexton SM; Marciniak MW; Gatton O; Shelton P
    J Am Pharm Assoc (2003); 2023; 63(1):389-395.e1. PubMed ID: 36369073
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Why aren't Australian pharmacists supplying naloxone? Findings from a qualitative study.
    Olsen A; Lawton B; Dwyer R; Taing MW; Chun KLJ; Hollingworth S; Nielsen S
    Int J Drug Policy; 2019 Jul; 69():46-52. PubMed ID: 31078908
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Assessing pharmacists' readiness to dispense naloxone and counsel on responding to opioid overdoses.
    Melaragni F; Levy C; Pedrazzi J; Andersen M
    J Am Pharm Assoc (2003); 2019; 59(4):550-554.e2. PubMed ID: 31109812
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Addressing the opioid epidemic through community pharmacy engagement: Study protocol for a randomized controlled trial.
    Gamble A; Mashburn T; Kennelty KA; Look KA; Westrick SC; Evon DM; Tudor G; Carpenter DM
    Contemp Clin Trials; 2022 Oct; 121():106920. PubMed ID: 36096283
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The feasibility of pharmacy-based naloxone distribution interventions: a qualitative study with injection drug users and pharmacy staff in Rhode Island.
    Zaller ND; Yokell MA; Green TC; Gaggin J; Case P
    Subst Use Misuse; 2013 Jun; 48(8):590-9. PubMed ID: 23750660
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Assessing pharmacy-based naloxone access using an innovative purchase trial methodology.
    Pollini RA; Joyce R; Ozga-Hess JE; Xuan Z; Green TC; Walley AY
    J Am Pharm Assoc (2003); 2020; 60(6):853-860. PubMed ID: 32651116
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Integration of Pharmacy Student Interns into a Naloxone Telephone Outreach Service.
    Rothbauer K; Genisot A; Frey T; JohnsonPharmacy William S Middleton Memorial Veterans Hospital D
    J Pain Palliat Care Pharmacother; 2022 Dec; 36(4):208-215. PubMed ID: 35997489
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Attitudes and availability: A comparison of naloxone dispensing across chain and independent pharmacies in rural and urban areas in Alabama.
    Sisson ML; McMahan KB; Chichester KR; Galbraith JW; Cropsey KL
    Int J Drug Policy; 2019 Dec; 74():229-235. PubMed ID: 31698165
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A qualitative examination of naloxone access in three states: Connecticut, Kentucky, and Wisconsin.
    Spector AL; Galletly CL; Christenson EA; Montaque HDG; Dickson-Gomez J
    BMC Public Health; 2022 Jul; 22(1):1387. PubMed ID: 35854278
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Public health detailing to increase naloxone access in NYC pharmacies.
    Foster CL; Tuazon E; Winkelstein E; Kunins HV; Kattan JA
    J Am Pharm Assoc (2003); 2023; 63(3):885-892. PubMed ID: 36997471
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Applying the capability, opportunity, motivation, and behavior model to identify opportunities to increase pharmacist comfort dispensing naloxone in Texas: A structural equation modeling approach.
    Varisco TJ; Downs CG; Rathburn KR; Fleming ML; Thornton JD
    Int J Drug Policy; 2020 Sep; 83():102827. PubMed ID: 32589581
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A qualitative study of a publicly funded pharmacy-dispensed naloxone program.
    Antoniou T; Pritlove C; Shearer D; Martins D; Tadrous M; Munro C; Gomes T
    Int J Drug Policy; 2021 Jun; 92():103146. PubMed ID: 33568317
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evaluation of a Program to Screen Patients in Community Pharmacies for Opioid Misuse and Accidental Overdose.
    Skoy E; Frenzel O; Eukel H; Lothspeich E; Steig J; Strand M; Werremeyer A
    Prev Chronic Dis; 2022 Jul; 19():E41. PubMed ID: 35834737
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Legal changes to increase access to naloxone for opioid overdose reversal in the United States.
    Davis CS; Carr D
    Drug Alcohol Depend; 2015 Dec; 157():112-20. PubMed ID: 26507172
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.